Recent Updates
Recently added Catalysts

MK0966 / Duration of Treatment: 1 Days

Phase 3

Pain, Postoperative Arthroscopy | Small molecule | Pain |Merck & Company, Inc.|Last Updated: Feb 2, 2017

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindUNCONTROLLEDBiomarker
Total Trials1
Total Enrollment420
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00390260Effect of Rofecoxib and a Narcotic Analgesic to Treat Pain Following Arthroscopic Surgery (0966-179)(COMPLETED)PHASE3 COMPLETED 420Feb 1, 2002Feb 1, 2003Feb 2, 2017 -
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Total Pain Relief over 6 hours following a single oral dose compared to placebo.
6 hours
Secondary Endpoints
Total Pain Relief over 6 hours following a single oral dose compared to hydrocodone + acetaminophen.
6 hours
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Interventions
NameTypeDescription
MK0966 / Duration of Treatment: 1 DaysDRUG -
Comparator: acetaminophen (+) hydrocodone bitartrate / Duration of Treatment: 1 DaysDRUG -
Comparator: placebo (unspecified) / Duration of Treatment: 1 DaysDRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 60 Years
SexALL
Healthy VolunteersNo

Inclusion Criteria: * Elective outpatient arthroscopic knee surgery expected to last \<= 90 minutes using general anesthesia * Patients must experience moderate to severe pain following surgery * Patient must be in general good health as judged by the primary investigator Exclusion Criteria: * Os...

Unlock Eligibility Criteria